Adverse event of ruxolitinib cream: a real-world analysis based on FDA Adverse Event Reporting System from 2021 to 2024
This study offers insights into the safety of ruxolitinib cream, improving understanding of its AEs and guiding safer clinical practices. However, the FAERS database lacks data on AE severity and the ability to establish causality, requiring further research to clarify mechanisms behind certain AEs.
Authors
- Jiangfeng Huang (ORCID: https://orcid.org/0009-0009-1657-204X)
- Shi Zhou (ORCID: https://orcid.org/0000-0001-9038-5984)
- Chuhan Fu (ORCID: https://orcid.org/0000-0003-0116-4675)
- Qinghai Zeng (ORCID: https://orcid.org/0000-0002-6747-1486)
- Keyi Zhang (ORCID: https://orcid.org/0009-0008-5489-4050)
- Jing Chen (ORCID: https://orcid.org/0000-0001-7130-7331)
- Lei Li (ORCID: https://orcid.org/0000-0002-9180-8552)
- Yaqing Wen (ORCID: https://orcid.org/0009-0006-7410-4832)
- Ling Jiang (ORCID: https://orcid.org/0000-0002-6589-1399)
Institutions
- Central South University (CN)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1080/14740338.2024.2446432
- Citations
- 3
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.27
Funders
- Natural Science Foundation of Hunan Province